Trial finds adding immune modulator to targeted therapy does not improve survival in difficult-to-treat thyroid cancer
byUniversity of Chicago Medical CenterCredit: Pixabay/CC0 Public DomainResults of a multicenter phase II clinical trial led by the University of Chicago Medicine Comprehensive Cancer Center show
Updated on: January 04,2024
Trial finds adding immune modulator to targeted therapy does not improve survival in difficult-to-treat thyroid cancer
byUniversity of Chicago Medical CenterCredit: Pixabay/CC0 Public DomainResults of a multicenter phase II clinical trial led by the University of Chicago Medicine Comprehensive Cancer Center show
Updated on:January 04,2024
